Gut Microbiome Metagenomics Analysis Suggests a Functional Model for the Development of Autoimmunity for Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Recent studies have suggested a bacterial role in the development of autoimmune disorders including type 1 diabetes (T1D). Over 30 billion nucleotide bases of Illumina shotgun metagenomic data were analyzed from stool samples collected from four pairs of matched T1D case-control subjects collected at the time of the development of T1D associated autoimmunity (i.e., autoantibodies). From these, approximately one million open reading frames were predicted and compared to the SEED protein database. Of the 3,849 functions identified in these samples, 144 and 797 were statistically more prevalent in cases and controls, respectively. Genes involved in carbohydrate metabolism, adhesions, motility, phages, prophages, sulfur metabolism, and stress responses were more abundant in cases while genes with roles in DNA and protein metabolism, aerobic respiration, and amino acid synthesis were more common in controls. These data suggest that increased adhesion and flagella synthesis in autoimmune subjects may be involved in triggering a T1D associated autoimmune response. Extensive differences in metabolic potential indicate that autoimmune subjects have a functionally aberrant microbiome. Mining 16S rRNA data from these datasets showed a higher proportion of butyrate-producing and mucin-degrading bacteria in controls compared to cases, while those bacteria that produce short chain fatty acids other than butyrate were higher in cases. Thus, a key rate-limiting step in butyrate synthesis is more abundant in controls. These data suggest that a consortium of lactate- and butyrate-producing bacteria in a healthy gut induce a sufficient amount of mucin synthesis to maintain gut integrity. In contrast, non-butyrate-producing lactate-utilizing bacteria prevent optimal mucin synthesis, as identified in autoimmune subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent findings linked an aberrant microbiome, which is generally represented by diminished diversity, including fewer butyrate-producing (butyrate was shown to trigger mucin production and hence gut integrity) and mucin-degrading bacteria,241 to the development of autoimmunity in T1DM.242”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [241]
The cited source says what the claim attributes to it.
In the citing paper
“The authors further indicate that a decrease in Prevotella might be related with a reduction in mucin synthesis which is associated with increased gut permeability (Brown et al., 2011;Forsyth et al., 2011) intensifying the translocation of bacterial antigens.”
From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as Brown et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Abnormalities of GI motility might increase the occurrence of SIBO which is highly prevalent in PD patients (Brown et al., 2011;Sánchez-Ferro et al., 2015), even in recently diagnosed PD patients (Tan et al., 2014).”
From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as Brown et al., 2011
Experimental — accuracy not yet measuredIn the citing paper
“As mentioned before, SIBO is highly prevalent in PD (Andrews et al., 2009;Brown et al., 2011) and PD patients that tested positive for SIBO are predisposed to worse motordysfunction (Tan et al., 2014).”
From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as Brown et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611 · cited 3×
“At the phylum level and at p-values less than 0.001, Actinobacteria, Bacteroidetes, and Proteobacteria were higher in cases while Firmicutes, Fusobacteria, Tenericutes, and Verrucomicrobia were higher in controls.”
BackgroundInfluentialGeneralized, Linear, and Mixed Models
McCulloch, C. E., & Searle, S. R. (2000) · Wiley Series in Probability and Statistics · doi:10.1002/0471722073 · Cited by 2,994
Review article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721 · cited 1×
“Butyrate is known as an anti-inflammatory short chain fatty acid that contributes to colon health [31–33].”
BackgroundThe Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases
Bach, J.-F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020100 · Cited by 2,687
Louis, P., & Flint, H. J. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2009.01514.x · Cited by 2,179 · cited 1×
“Butyrate is known as an anti-inflammatory short chain fatty acid that contributes to colon health [31–33].”
BackgroundPeng, L., Li, Z.-R., Green, R. S., Holzmanr, I. R., & Lin, J. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.104638 · Cited by 2,130
Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium
Derrien, M., Vaughan, E. E., Plugge, C. M., & de Vos, W. M. (2004) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijs.0.02873-0 · Cited by 2,094 · cited 2×
“Perspective signatures of increased mucin synthesis in the gut may be the presence of Prevotella and Akkermansia as both genera are known to degrade mucin [30,39].”
BackgroundInnate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921 · cited 2×
“Intestinal microbes and the innate immune system also interact to affect the development of diabetes in NOD mice [15].”
BackgroundMucin dynamics and enteric pathogens
McGuckin, M. A., Lindén, S. K., Sutton, P., & Florin, T. H. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2538 · Cited by 1,428 · cited 1×
“Mucin is well known as a glycoprotein produced by the host that contributes to gut integrity [42].”
BackgroundThe microbiology of butyrate formation in the human colon
Pryde, S. E., Duncan, S. H., Hold, G. L., Stewart, C. S., & Flint, H. J. (2002) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2002.tb11467.x · Cited by 1,320 · cited 1×
“Butyrate is known as an anti-inflammatory short chain fatty acid that contributes to colon health [31–33].”
BackgroundToward defining the autoimmune microbiome for type 1 diabetes
Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Novelo, L. L., Casella, G., Drew, J. C., Ilonen, J., Knip, M., Hyöty, H., et al. (2011) · The ISME Journal · doi:10.1038/ismej.2010.92 · Cited by 806 · cited 14×
“The samples used in this study came from eight Finnish children described previously [22].”
BackgroundMethodResultInfluentialSelf-citationThe Mucin Degrader Akkermansia muciniphila Is an Abundant Resident of the Human Intestinal Tract
Derrien, M., Collado, M. C., Ben-Amor, K., Salminen, S., & de Vos, W. M. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.01226-07 · Cited by 658 · cited 1×
“These bacteria are mucin degraders [39], often found in the human gut [43], and this work suggests that they may be useful indicators of gut integrity.”
BackgroundBurger-van Paassen, N., Vincent, A., Puiman, P. J., van der Sluis, M., Bouma, J., Boehm, G., van Goudoever, J. B., van Seuningen, I., & Renes, I. B. (2009) · Biochemical Journal · doi:10.1042/bj20082222 · Cited by 611
Yadav, H., Jain, S., & Sinha, P. R. (2007) · Nutrition · doi:10.1016/j.nut.2006.09.002 · Cited by 587 · cited 1×
“Likewise, both the NOD mouse and BB-DP rats treated with Freund’s adjuvants or Lactobacillus strains delayed or decreased incidence of diabetes [8–16].”
BackgroundPeng, L., He, Z., Chen, W., Holzman, I. R., & Lin, J. (2007) · Pediatric Research · doi:10.1203/01.pdr.0000250014.92242.f3 · Cited by 518 · cited 1×
“In addition, butyrate induces mucin synthesis [34,35], decreases bacterial transport across metabolically stressed epithelia [36], and improves the intestinal barrier by increasing tight junction assembly [37,38].”
BackgroundControl of intestinal inflammation by regulatory T cells
Singh, B., Read, S., Asseman, C., Malmström, V., Mottet, C., Stephens, L. A., Stepankova, R., Tlaskalova, H., & Powrie, F. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820115.x · Cited by 500
The “Perfect Storm” for Type 1 Diabetes
Vaarala, O., Atkinson, M. A., & Neu, J. (2008) · Diabetes · doi:10.2337/db08-0331 · Cited by 497 · cited 2×
“[3], the host may be leaking more”
BackgroundSelf-citationMolecular analysis of the gut microbiota of identical twins with Crohn's disease
Dicksved, J., Halfvarson, J., Rosenquist, M., Järnerot, G., Tysk, C., Apajalahti, J., Engstrand, L., & Jansson, J. K. (2008) · The ISME Journal · doi:10.1038/ismej.2008.37 · Cited by 459 · cited 1×
“Fecal microbial communities in identical twins with Crohn’s disease show a decrease in diversity when compared to healthy twins; likewise, the microbial communities of the twins with Crohn’s disease were less similar to one another than the communities from the healthy individuals [19].”
BackgroundKarvonen, M., Tuomilehto, J., Libman, I., & LaPorte, R. (1993) · Diabetologia · doi:10.1007/bf02374468 · Cited by 382
Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon
Barcelo, A., Claustre, J., Moro, F., Chayvialle, J.-A., Cuber, J.-C., & Plaisancié, P. (2000) · Gut · doi:10.1136/gut.46.2.218 · Cited by 375 · cited 1×
“Unlike butyrate, these short chain fatty acids do not induce mucin synthesis [34,35,40,41].”
BackgroundCalcinaro, F., Dionisi, S., Marinaro, M., Candeloro, P., Bonato, V., Marzotti, S., Corneli, R. B., Ferretti, E., Gulino, A., Grasso, F., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1831-2 · Cited by 352 · cited 1×
“Likewise, both the NOD mouse and BB-DP rats treated with Freund’s adjuvants or Lactobacillus strains delayed or decreased incidence of diabetes [8–16].”
BackgroundEnhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate†
Lewis, K., Lutgendorff, F., Phan, V., Söderholm, J. D., Sherman, P. M., & McKay, D. M. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21177 · Cited by 335 · cited 1×
“In addition, butyrate induces mucin synthesis [34,35], decreases bacterial transport across metabolically stressed epithelia [36], and improves the intestinal barrier by increasing tight junction assembly [37,38].”
BackgroundBrugman, S., Klatter, F. A., Visser, J. T. J., Wildeboer-Veloo, A. C. M., Harmsen, H. J. M., Rozing, J., & Bos, N. A. (2006) · Diabetologia · doi:10.1007/s00125-006-0334-0 · Cited by 332 · cited 1×
“Of those factors, the gut microbiota have come under recent interest; supported in part by observations in both non-obese diabetic (NOD) mice and BioBreeding Diabetes Prone (BB-DP) rats where antibiotic use prevents the onset of diabetes [4,5].”
BackgroundGeneralized Linear Mixed Models
McCulloch, C. E. (2001) · Encyclopedia of Environmetrics · doi:10.1002/9780470057339.vag009 · Cited by 295
Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats
Valladares, R., Sankar, D., Li, N., Williams, E., Lai, K.-K., Abdelgeliel, A. S., Gonzalez, C. F., Wasserfall, C. H., Larkin, J., Schatz, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010507 · Cited by 279 · cited 1×
“Likewise, both the NOD mouse and BB-DP rats treated with Freund’s adjuvants or Lactobacillus strains delayed or decreased incidence of diabetes [8–16].”
BackgroundSelf-citationPrevention of Type I Diabetes in NOD Mice by Adjuvant Immunotherapy
Sadelain, M. W. J., Qin, H.-Y., Lauzon, J., & Singh, B. (1990) · Diabetes · doi:10.2337/diab.39.5.583 · Cited by 275
Roesch, L. F. W., Lorca, G. L., Casella, G., Giongo, A., Naranjo, A., Pionzio, A. M., Li, N., Mai, V., Wasserfall, C. H., Schatz, D., et al. (2009) · The ISME Journal · doi:10.1038/ismej.2009.5 · Cited by 242
Self-citationColonic mucin synthesis is increased by sodium butyrate.
Finnie, I. A., Dwarakanath, A. D., Taylor, B. A., & Rhodes, J. M. (1995) · Gut · doi:10.1136/gut.36.1.93 · Cited by 231 · cited 2×
“In addition, butyrate induces mucin synthesis [34,35], decreases bacterial transport across metabolically stressed epithelia [36], and improves the intestinal barrier by increasing tight junction assembly [37,38].”
BackgroundSpecific Amino Acids Increase Mucin Synthesis and Microbiota in Dextran Sulfate Sodium–Treated Rats
Faure, M., Mettraux, C., Moennoz, D., Godin, J.-P., Vuichoud, J., Rochat, F., Breuillé, D., Obled, C., & Corthésy-Theulaz, I. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.6.1558 · Cited by 188
2. Random-Effects Modeling of Categorical Response Data
Agresti, A., Booth, J. G., Hobert, J. P., & Caffo, B. (2000) · Sociological Methodology · doi:10.1111/0081-1750.t01-1-00075 · Cited by 183
Patterson, C. C., Dahlquist, G., Soltész, G., Green, A., & on behalf of the EURODIAB ACE Study Group (2001) · Diabetologia · doi:10.1007/pl00002961 · Cited by 179
MATSUZAKI, T., NAGATA, Y., KADO, S., UCHIDA, K., KATO, I., HASHIMOTO, S., & YOKOKURA, T. (1997) · APMIS · doi:10.1111/j.1699-0463.1997.tb05066.x · Cited by 175 · cited 1×
“Likewise, both the NOD mouse and BB-DP rats treated with Freund’s adjuvants or Lactobacillus strains delayed or decreased incidence of diabetes [8–16].”
BackgroundShort chain fatty acids but not lactate or succinate stimulate mucus release in the rat colon
Shimotoyodome, A., Meguro, S., Hase, T., Tokimitsu, I., & Sakata, T. (2000) · Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology · doi:10.1016/s1095-6433(00)00183-5 · Cited by 172 · cited 1×
“Unlike butyrate, these short chain fatty acids do not induce mucin synthesis [34,35,40,41].”
BackgroundInhibition of Type 1 Diabetes Correlated to a Lactobacillus johnsonii N6.2-Mediated Th17 Bias
Lau, K., Benitez, P., Ardissone, A., Wilson, T. D., Collins, E. L., Lorca, G., Li, N., Sankar, D., Wasserfall, C., Neu, J., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001864 · Cited by 158 · cited 1×
“In addition, Lactobacillus strains can induce specific changes in the immune system of NOD mice that can increase or decrease diabetes [45].”
BackgroundSelf-citationKing, C., & Sarvetnick, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017049 · Cited by 157 · cited 1×
“Initial studies found that NOD mice raised in germfree environments would spontaneously develop diabetes [6], while a recent study suggested that rather than being diminished under germ-free conditions, the development of T1D can be prevented through modulation of the intestinal microbiota [7].”
BackgroundInfluence of Fecal Sample Storage on Bacterial Community Diversity
Roesch, L. F. W., Casella, G., Simell, O., Krischer, J. P., Wasserfall, C. H., Schatz, D., Atkinson, M. A., Neu, J., & Triplett, E. W. (2009) · The Open Microbiology Journal · doi:10.2174/1874285800903010040 · Cited by 155
Self-citationPrevention of Insulitis and Diabetes Onset by Treatment With Complete Freund's Adjuvant in NOD Mice
McInerney, M. F., Pek, S., & Thomas, D. W. (1991) · Diabetes · doi:10.2337/diab.40.6.715 · Cited by 135
Alyanakian, M., Grela, F., Aumeunier, A., et al. (2006) · PubMed · Cited by 85
Alyanakian, M. (2006) · Diabetes · doi:10.2337/diabetes.55.1.179 · Cited by 84
Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant
Sadelain, M., Qin, H.-Y., SUMOSKI, W., Parfrey, N. A., Singh, B., & Rabinovitch, A. (1990) · Journal of Autoimmunity · doi:10.1016/s0896-8411(05)80034-4 · Cited by 77
Alyanakian, M., Grela, F., Aumeunier, A., Chiavaroli, C., Gouarin, C., Bardel, É., Normier, G., Chatenoud, L., Thiéblemont, N., & Bach, J. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0189 · Cited by 73 · cited 1×
“Likewise, both the NOD mouse and BB-DP rats treated with Freund’s adjuvants or Lactobacillus strains delayed or decreased incidence of diabetes [8–16].”
BackgroundGiongo, A., Davis‐Richardson, A. G., Crabb, D. B., & Triplett, E. W. (2010) · Diversity · doi:10.3390/d2071015 · Cited by 62
Self-citationChow, J., & Mazmanian, S. K. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2008.12.006 · Cited by 54
Schwartz, R. F., Neu, J., Schatz, D., Atkinson, M. A., & Wasserfall, C. H. (2006) · Diabetologia · doi:10.1007/s00125-006-0526-7 · Cited by 50
Self-citationWright, D. P., Knight, C. G., Parkar, S. G., Christie, D. L., & Roberton, A. M. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.11.3002-3007.2000 · Cited by 47 · cited 2×
“Perspective signatures of increased mucin synthesis in the gut may be the presence of Prevotella and Akkermansia as both genera are known to degrade mucin [30,39].”
BackgroundFischer, C. R., Tseng, H.-C., Tai, M., Prather, K. L. J., & Stephanopoulos, G. N. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2749-2 · Cited by 42 · cited 1×
“coli [29].”
Quantitative Metagenomic Analyses Based on Average Genome Size Normalization
Frank, J. A., & Sørensen, S. J. (2011) · Applied and Environmental Microbiology · doi:10.1128/aem.02167-10 · Cited by 40
Cited by
The role of short chain fatty acids in health and disease
Tan, J., McKenzie, C., Potamitis, M., Thorburn, A. N., Mackay, C. R., & Macia, L. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800100-4.00003-9 · Cited by 2,425
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity
Markle, J. G. M., Frank, D. N., Mortin-Toth, S., Robertson, C. E., Feazel, L. M., Rolle-Kampczyk, U., von Bergen, M., McCoy, K. D., Macpherson, A. J., & Danska, J. S. (2013) · Science · doi:10.1126/science.1233521 · Cited by 2,025
Temporal development of the gut microbiome in early childhood from the TEDDY study
Stewart, C. J., Ajami, N. J., O’Brien, J. L., Hutchinson, D. S., Smith, D. P., Wong, M. C., Ross, M. C., Lloyd, R. E., Doddapaneni, H., Metcalf, G. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0617-x · Cited by 2,014
Self-citationGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
“Decreased Prevotellaceae abundance also fits well with observations of increased gut permeability in PD because low Prevotella levels may indicate decreased mucin synthesis, which is associated with increased gut permeability.(53,71) Increased mucosal permeability could lead to local and systemic exposure to bacterial…”
Background
Metadata
- Authors
- Brown, C. T., Davis-Richardson, A. G., Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Casella, G., Drew, J. C., Ilonen, J., Knip, M., Hyöty, H., Veijola, R., Simell, T., Simell, O., Neu, J., Wasserfall, C. H., Schatz, D., Atkinson, M. A., & Triplett, E. W.
- Affiliations
- University of Florida (US)
- University of Eastern Finland (FI)
- University of Helsinki (FI)
- Tampere University Hospital (FI)
- University of Oulu (FI)
- Turku University Hospital (FI)
- Corresponding author
- Triplett, Eric W.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-17
- Volume
- 6
- Issue
- 10
- Pages
- e25792
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3197175
- OpenAlex
- W2060915038
- Cited by
- 778
- References
- 48
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 53 · 2023: 60 · 2022: 69 · 2021: 73 · 2020: 66 · 2019: 69 · 2018: 68 · 2017: 59 · 2016: 55 · 2015: 49 · 2014: 47 · 2013: 38 · 2012: 22
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- type 1 diabetes, gut microbiota, autoimmunity, autoantibodies, metagenomics, bacterial gene function, carbohydrate metabolism, bacterial adhesion, flagella synthesis, butyrate production, short-chain fatty acids, mucin degradation, intestinal barrier integrity, lactate-utilizing bacteria, 16S rRNA
- MeSH terms
- Autoantibodies, Butyrates, Diabetes Mellitus, Type 1, Fatty Acids, Volatile, Humans, Mucins, RNA, Ribosomal, 16S, Autoimmunity, Case-Control Studies, Databases, Nucleic Acid, Gastrointestinal Tract, Metagenome, Metagenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.